Agnieszka Piotrowska-Seweryn

Mucoepidermoid carcinoma in Warthin tumor of the parotid gland

Neoplasms of salivary glands are responsible for ca. 3–5% of head and neck tumors, and they usually occur in the parotid gland (80%) as benign tumors (80%). Localization in submandibular salivary glands is reported in 10–20% of cases, and tumors sited in sublingual and minor salivary glands are very rare (several percent) [1]. Among benign neoplasms the following types have been identified: pleomorphic adenoma (80%), adenolymphoma (12%) and others (2%) [2].

Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: A pilot study

Background According to recent studies, the newest strategy for the treatment of exudative age-related macular degeneration is to combine anti-VEGF agents with non-steroid anti-inflammatory drugs (NSAIDs) such as nepafenac and bromfenac to decrease the frequency of intravitreal injections. Since most research has focused on ranibizumab, the aim of this study is to evaluate whether an alternative drug such as bevacizumab could lead to similar outcomes. Material/Methods The study was conducted on a group of 26 patients who were administered intravitreal bevacizumab and topical bromfenac (study group) and 26 patients with single bevacizumab therapy (control group). Cases that were not qualified for ranibizumab therapy were included in the study group. Results The study revealed that the visual acuity and parameters observed in OCT improved more in the study group than in the control group. However, the correlations between the above factors and the frequency of intravitreal injections were statistically significant only in visual acuity. Conclusions We recommend the combined therapy of bevacizumab and bromfenac as an alternative and beneficial method of treatment in patients with exudative AMD who do not qualify for ranibizumab therapy. This combined therapy might efficiently reduce the number of intravitreal injections of bevacizumab.

Fibrous dysplasia of sphenoid bone – diagnostic difficulties

STRESZCZENIE: Dysplazja włóknista kości jest łagodną zmianą o niedokładnie poznanej etiologii. Istotą choroby jest zastąpienie prawidłowego utkania kostnego przez tkankę włóknistą. Lokalizacja w kości klinowej jest niezwykle rzadka. Badanie histopatomorfologiczne jest niezbędne do potwierdzenia rozpoznania. W niniejszej pracy autorzy prezentują przypadek 58-letniej pacjentki z dysplazją włóknistą kości klinowej. Chora uskarżała się na bóle głowy trwające od wielu lat, bez innych objawów towarzyszących. Wykonane badania obrazowe MRI i TK nie potwierdziły jednoznacznie łagodnego charakteru zmiany, jednak wyniki biopsji wykonanej z dostępu endoskopowego z wykorzystaniem neuronawigacji wykazały obecność dysplazji włóknistej kości klinowej.

Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD

Background Among many protocols for treatment of exudative AMD, combined therapy of anti-VEGF agents and non-steroidal anti-inflammatory drugs (NSAIDs) seems to be an ideal alternative to monotherapy based on ranibizumab or bevacizumab. The aim of this study was to evaluate the effectiveness of aflibercept and bromfenac in the treatment of exudative AMD. Material/Methods The study was conducted on a group of 27 patients with exudative AMD who were administered intravitreal aflibercept and topical bromfenac (study group) once a month. Additional injections were administered up to 3 months after the third administration, depending on response to treatment. The control group consisted of subjects treated with aflibercept only. Visual acuity and anatomical outcomes in optical coherence tomography (OCT) were assessed at baseline visit, 4 months after the first dose, and 6 months after the start of the treatment. Results Visual acuity improved over time in the study group and the differences between the groups were statistically significant. No statistically significant differences were found in OCT parameters. Conclusions Combined therapy of aflibercept and bromfenac in the treatment of wet AMD is more effective than single aflibercept therapy.

Endoscopic approach to the resection of adenoid cystic carcinoma of paranasal sinuses and nasal cavity: case report and own experience

AbstractAdenoid cystic carcinoma (ACC) is a rare malignant tumor that might occur in nasal cavity and paranasal sinuses. It is characteristic for poor prognosis, especially the solid histopathological subtype of the tumor. ACC might spread along nerves and fascias and it is usually diagnosed at advanced stage. Computed tomography and magnetic resonance imaging together with fine-needle biopsy are the gold standards in the diagnostic procedure of the cancer. Surgery with adjuvant therapy are the most common methods of treatment. Among the surgical approaches, the functional endonasal sinus surgery seems to be the most appropriate and favorable way of treatment. In the study, the authors present a case of a 62-year-old patient with T4aN0M0 ACC tumor treated endoscopically at the Department of Laryngology and ENT Oncology, WSS No. 5 in Sosnowiec. The authors indicate the usefulness of FESS procedure in the treatment of malignancies of nasal cavity and paranasal sinuses. They also review the recent publications on endonasal versus open approach in similar cases. In conclusions, the authors favor endonasal approach as a mini-invasive method of surgical treatment of ACC of paranasal sinuses that results in satisfactory oncological outcome and high quality of patient’s life.